ALLIGATOR BIOSCIENCE Aktie

>ALLIGATOR BIO Performance

1 Woche: -98,7%

1 Monat: 0%

3 Monate: -99,1%

6 Monate: -99,9%

1 Jahr: 0%

laufendes Jahr: -99,1%

>ALLIGATOR BIOSCIENCE Aktie

Name:

ALLIGATOR BIOSCIENCE

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0024173637 / A41BED

Symbol/ Ticker:

7AL0 (Frankfurt)

Kürzel:

FRA:7AL0, ETR:7AL0, 7AL0:GR

Index:

Webseite:

https://alligatorbioscien..

Profil:

Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune sys..
>Volltext..

Marktkapitalisierung:

8.25 Mio. EUR

Unternehmenswert:

6.5 Mio. EUR

Umsatz:

0.05 Mio. EUR

EBITDA:

-11.43 Mio. EUR

Nettogewinn:

-4.81 Mio. EUR

Gewinn je Aktie:

-0.1 EUR

Schulden:

4.04 Mio. EUR

Liquide Mittel:

5.83 Mio. EUR

Operativer Cashflow:

-14.62 Mio. EUR

Bargeldquote:

0.8

Umsatzwachstum:

-99.06%

Gewinnwachstum:

76.74%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ALLIGATOR BIOSCIENCE, ALLIGATOR BIO

Letzte Datenerhebung:

06.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 534.52 Mio. St.

Frei handelbar: 97.68%

Leerverk. Aktien: -

Rückkaufquote: -299.05%

Mitarbeiter: 11

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: 80.84%

Bewertung:

KGV: -

KGV lG: -

KUV: 63.68

KBV: 1.06

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -9990.27%

Operative Marge: -24100.97%

Managementeffizenz:

Gesamtkaprendite: -47.78%

Eigenkaprendite: -

>Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>ALLIGATOR BIO Chart & Kurs - Stuttgart

>ALLIGATOR BIO News

30.03.26 - 09:31	Notice of Annual General Meeting in Alligator Bioscience AB (Accesswire)
	The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, SE / ACCESS Newswire / March ......

27.03.26 - 11:54	The Nomination Committee′s Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (Accesswire)
	LUND, SE / ACCESS Newswire / March 27, 2026 / Alligator Bioscience (STO:ATORX) - The Nomination Committee of Alligator Bioscience AB (publ) ("Alligator Bioscience") proposes re-election of Hans-Pet......

26.03.26 - 15:31	Alligator Bioscience Publishes Annual Report for 2025 (Accesswire)
	LUND, SWEDEN / ACCESS Newswire / March 26, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that the Annual Report for 2025, as well as the company's Remuneration Report, has be......

10.03.26 - 13:54	Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform (Accesswire)
	LUND, SWEDEN / ACCESS Newswire / March 10, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced ......

02.03.26 - 09:18	Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22 (Accesswire)
	LUND, SE / ACCESS Newswire / March 2, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed......

27.02.26 - 18:54	Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB (Accesswire)
	NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH A......

12.02.26 - 08:54	Alligator Bioscience AB (publ) GAAP EPS of -SEK 0.66, revenue of SEK 46K (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 08:30	Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update (Accesswire)
	Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026.Mitazalimab validation: OPTIMIZE-1 biomarker......

05.02.26 - 09:30	Invitation to Alligator Bioscience′s Earnings Call on 12 February 2026 (Accesswire)
	LUND, SE / ACCESS Newswire / February 5, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody d......

30.01.26 - 15:30	Change in Number of Shares and Votes in Alligator Bioscience AB (Accesswire)
	LUND, SWEDEN / ACCESS Newswire / January 30, 2026 / Alligator Bioscience (STO:ATORX) - During January 2026, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has in......

09.01.26 - 09:06	Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026 (Accesswire)
	LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today ......

19.12.25 - 12:55	Alligator Bioscience Announces Preliminary Outcome in Rights Issue (Accesswire)
	NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH A......

09.12.25 - 12:30	Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer (Accesswire)
	LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for P......

03.12.25 - 18:30	Alligator Bioscience: Alligator Publishes Supplement Prospectus (Accesswire)
	NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH A......

03.12.25 - 09:30	Alligator Bioscience Publishes Financial Calendar for 2026 (Accesswire)
	LUND, SE / ACCESS Newswire / December 3, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), hereby publishes its financial calendar for 2026:Deadline for Alligator Bioscience's shareh......

01.12.25 - 19:06	Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue (Accesswire)
	NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH A......

01.12.25 - 09:18	Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications (Accesswire)
	LUND, SE / ACCESS Newswire / December 1, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today announced the publication of a peer-reviewed article in Nature communications, reporti......

25.11.25 - 12:06	Bulletin from The Extraordinary General Meeting in Alligator Bioscience AB (Accesswire)
	LUND, SE / ACCESS Newswire / November 25, 2025 / Alligator Bioscience (STO:ATORX) - Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of th......

05.11.25 - 11:30	Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting (Accesswire)
	LUND, SE / ACCESS Newswire / November 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today......

03.11.25 - 15:30	Nomination Committee Appointed in Respect of AGM 2026 in Alligator Bioscience AB (Accesswire)
	LUND, SWEDEN / ACCESS Newswire / November 3, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, t......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram